Matthew G Laporte

Title: Matthew G. Laporte: Innovator in Pharmaceutical Compositions

Introduction

Matthew G. Laporte is a notable inventor in the field of pharmaceutical compositions. He has contributed to the development of innovative compounds that have potential therapeutic applications. His work primarily focuses on the interaction of molecules with apoptosis proteins, which plays a crucial role in cell regulation.

Latest Patents

Matthew G. Laporte holds patents for significant inventions, including the "Smac Mimetic," which involves a SMAC mimetic and pharmaceutical compositions thereof, along with methods of use. Another notable patent is for "IAP Binding Compounds," which discloses IAP binding molecules and compositions. These molecules interact with inhibitor of apoptosis proteins (IAPs) in cells and may be utilized to modify apoptosis in treated cells. The embodiments of these compounds have a Kd of less than 0.1 micromolar, showcasing their potential effectiveness. Methods for using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.

Career Highlights

Throughout his career, Matthew G. Laporte has worked with various organizations, including Tetralogic Pharmaceuticals Corporation. His contributions to the field have been recognized for their potential impact on therapeutic strategies.

Collaborations

Matthew has collaborated with notable individuals such as Stephen M. Condon and Yijun Deng, enhancing the scope and depth of his research.

Conclusion

Matthew G. Laporte is a distinguished inventor whose work in pharmaceutical compositions has the potential to influence therapeutic practices significantly. His innovative approaches to IAP binding molecules and SMAC mimetics highlight his contributions to the field of medicine.